Furthermore, survival analysis demonstrated that HCC patients with high NAT10 expression exhibited significantly poorer disease‐specific survival and shorter progression‐free intervals (Figure S1H,I). The gene discussed is NAT10; the disease is hepatocellular carcinoma.